Dr. Reddy's Laboratories Agreed To Partially Defer A Milestone Payment From Citius Oncology, Inc., Due On September 9, 2024, Upon FDA Approval Of LYMPHIR, Without Penalty, Pending Further Discussions, As Per Their 2021 Asset Purchase Agreement
Dr. Reddy's Laboratories Agreed To Partially Defer A Milestone Payment From Citius Oncology, Inc., Due On September 9, 2024, Upon FDA Approval Of LYMPHIR, Without Penalty, Pending Further Discussions, As Per Their 2021 Asset Purchase Agreement
Pending further discussions with Dr. Reddy's Laboratories SA, a subsidiary of Dr. Reddy's Laboratories, Ltd. (collectively, "Dr. Reddy's"), Dr. Reddy's agreed to a partial deferral without penalty of a milestone payment by Citius Oncology, Inc. (the "Company"), which was triggered upon regulatory approval of LYMPHIRTM by the U.S. Food and Drug Administration and due on September 9, 2024, pursuant to the terms of the Asset Purchase Agreement, dated as of September 1, 2021, between Dr. Reddy's and Citius Pharmaceuticals, Inc. (the "Asset Purchase Agreement").
在與Dr. Reddy's Laboratories SA工作室的進一步討論後，Dr. Reddy's同意對Citius Oncology, Inc.（以下簡稱"公司"）的一筆里程碑支付進行部分延期，延期期間沒有罰金。該里程碑支付是根據2021年9月1日Dr. Reddy's和Citius Pharmaceuticals, Inc.之間的資產購買協議（以下簡稱"購買協議"）的條款，在LYMPHIRTm獲得美國食品和藥物管理局的監管批准後觸發，並且應於2024年9月9日到期。
譯文內容由第三人軟體翻譯。